- Home
- THCH vs VOR Comparison
THCH vs VOR Comparison
Compare THCH & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | THCH | VOR |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.5M | 207.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | THCH | VOR |
|---|---|---|
| Price | $2.20 | $12.38 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $66.63 |
| AVG Volume (30 Days) | 10.2K | ★ 3.5M |
| Earning Date | 12-09-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $188,274,078.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.95 | $2.62 |
| 52 Week High | $3.82 | $65.80 |
Technical Indicators
Market Signals| Indicator | THCH | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 30.63 | 49.49 |
| Support Level | $2.25 | $7.91 |
| Resistance Level | $2.39 | $16.80 |
| Average True Range (ATR) | 0.10 | 1.70 |
| MACD | -0.04 | 0.99 |
| Stochastic Oscillator | 8.33 | 54.74 |
Price Performance
Historical ComparisonAbout THCH TH International Limited Ordinary shares
TH International Ltd is the parent company of the franchise of Tim Hortons coffee shops and has the rights to operate Tim Hortons coffee shops in mainland China, Hong Kong, and Macau. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. The Company operated under single reportable segment, Tim Hortons. The company's revenue is derived from its operations in the PRC.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.